Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature. (Q52760450)
Jump to navigation
Jump to search
scientific article published in August 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature. |
scientific article published in August 2017 |
Statements
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature (English)
Aimee E Houlton
Lynn Swun Quek
Paul Ferguson
Emma Gbandi
Corran Roberts
Marlen Metzner
Natalia Garcia-Martin
Angela Hamblin
Sandeep Nagra
Louise Dudley
Keith Wheatley
Mary Frances McMullin
Srinivas P Pillai
Richard J Kelly
Shamyla Siddique
Michael Dennis
Jamie D Cavenagh